BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 33198356)

  • 21. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.
    Ben Sahra I; Laurent K; Giuliano S; Larbret F; Ponzio G; Gounon P; Le Marchand-Brustel Y; Giorgetti-Peraldi S; Cormont M; Bertolotto C; Deckert M; Auberger P; Tanti JF; Bost F
    Cancer Res; 2010 Mar; 70(6):2465-75. PubMed ID: 20215500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
    Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor.
    Ueno S; Kimura T; Yamaga T; Kawada A; Ochiai T; Endou H; Sakurai H
    J Pharmacol Sci; 2016 Jun; 131(2):110-7. PubMed ID: 27262901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin attenuates graft-versus-host disease via restricting mammalian target of rapamycin/signal transducer and activator of transcription 3 and promoting adenosine monophosphate-activated protein kinase-autophagy for the balance between T helper 17 and Tregs.
    Park MJ; Lee SY; Moon SJ; Son HJ; Lee SH; Kim EK; Byun JK; Shin DY; Park SH; Yang CW; Cho ML
    Transl Res; 2016 Jul; 173():115-130. PubMed ID: 27126953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Negative regulation of the LKB1/AMPK pathway by ERK in human acute myeloid leukemia cells.
    Kawashima I; Mitsumori T; Nozaki Y; Yamamoto T; Shobu-Sueki Y; Nakajima K; Kirito K
    Exp Hematol; 2015 Jul; 43(7):524-33.e1. PubMed ID: 25846811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
    Tseng CH
    Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer.
    Ranasinghe WKB; Williams S; Ischia J; Wetherell D; Baldwin G; Shulkes A; Sengupta S; Bolton D; Patel O
    BJU Int; 2019 May; 123 Suppl 5():36-42. PubMed ID: 31012989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
    Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
    Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?
    Kezic A; Popovic L; Lalic K
    Oxid Med Cell Longev; 2018; 2018():2640342. PubMed ID: 30034573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin Has Positive Therapeutic Effects in Colon Cancer and Lung Cancer.
    Henderson D; Frieson D; Zuber J; Solomon SS
    Am J Med Sci; 2017 Sep; 354(3):246-251. PubMed ID: 28918830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
    Richards KA; Liou JI; Cryns VL; Downs TM; Abel EJ; Jarrard DF
    J Urol; 2018 Dec; 200(6):1256-1263. PubMed ID: 29940252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway.
    Kumar D; Shankar S; Srivastava RK
    Cancer Lett; 2014 Feb; 343(2):179-89. PubMed ID: 24125861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Metformin and AMPK: an old drug and a new enzyme in the context of metabolic syndrome].
    Santomauro Júnior AC; Ugolini MR; Santomauro AT; Souto RP
    Arq Bras Endocrinol Metabol; 2008 Feb; 52(1):120-5. PubMed ID: 18345405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New perspectives for metformin in cancer therapy].
    Loubière C; Dirat B; Tanti JF; Bost F
    Ann Endocrinol (Paris); 2013 May; 74(2):130-6. PubMed ID: 23587351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.
    Shen X; Zhao Y; Liu G; Zhou HL; Fan J; Zhang L; Li YL; Wang Y; Liang J; Xu ZX
    Life Sci; 2020 Sep; 256():117923. PubMed ID: 32522567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin: a modulator of bevacizumab activity in cancer? A case report.
    Indraccolo S; Randon G; Zulato E; Nardin M; Aliberti C; Pomerri F; Casarin A; Nicoletto MO
    Cancer Biol Ther; 2015; 16(2):210-4. PubMed ID: 25607951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin in prostate cancer: two for the price of one.
    Clements A; Gao B; Yeap SHO; Wong MKY; Ali SS; Gurney H
    Ann Oncol; 2011 Dec; 22(12):2556-2560. PubMed ID: 21421541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Metformin--new treatment strategies for gynecologic neoplasms].
    Milewicz T; Kiałka M; Mrozińska S; Ociepka A; Krzysiek J
    Przegl Lek; 2013; 70(2):81-4. PubMed ID: 23879009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.
    Ben Sahra I; Regazzetti C; Robert G; Laurent K; Le Marchand-Brustel Y; Auberger P; Tanti JF; Giorgetti-Peraldi S; Bost F
    Cancer Res; 2011 Jul; 71(13):4366-72. PubMed ID: 21540236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
    Pencik J; Philippe C; Schlederer M; Atas E; Pecoraro M; Grund-Gröschke S; Li WJ; Tracz A; Heidegger I; Lagger S; Trachtová K; Oberhuber M; Heitzer E; Aksoy O; Neubauer HA; Wingelhofer B; Orlova A; Witzeneder N; Dillinger T; Redl E; Greiner G; D'Andrea D; Östman JR; Tangermann S; Hermanova I; Schäfer G; Sternberg F; Pohl EE; Sternberg C; Varady A; Horvath J; Stoiber D; Malcolm TI; Turner SD; Parkes EE; Hantusch B; Egger G; Rose-John S; Poli V; Jain S; Armstrong CWD; Hoermann G; Goffin V; Aberger F; Moriggl R; Carracedo A; McKinney C; Kennedy RD; Klocker H; Speicher MR; Tang DG; Moazzami AA; Heery DM; Hacker M; Kenner L
    Mol Cancer; 2023 Aug; 22(1):133. PubMed ID: 37573301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.